US Stock Insider Trading | Spero Therapeutics disclosed 1 insider transaction on February 4

2026-02-20 13:52:20

On February 4, 2026, Spero Therapeutics (SPRO) disclosed an insider transaction. Executive Esther Rajavelu sold 18,400 shares on February 2, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 4, 2026	Executive	Esther Rajavelu	February 2, 2026	Sell	18,400	2.20	40,600
November 12, 2025	Executive	Esther Rajavelu	November 7, 2025	Sell	40,300	2.37	95,400
September 3, 2025	Executive	Timothy Keutzer	August 28, 2025	Sell	1,695	1.97	3,339.15
September 3, 2025	Director	Ankit Mahadevia	August 28, 2025	Sell	6,572	1.97	12,900
February 5, 2025	Director	Ankit Mahadevia	February 5, 2025	Sell	69,200	0.78	54,000
February 5, 2025	Executive	Esther Rajavelu	February 5, 2025	Sell	20,700	0.78	16,100
February 5, 2025	Executive	Sath Shukla	February 5, 2025	Sell	155,300	0.78	121,200
February 5, 2025	Executive	Timothy Keutzer	February 5, 2025	Sell	56,500	0.78	44,100
November 12, 2024	Executive	Esther Rajavelu	November 7, 2024	Sell	23,400	1.31	30,600
November 12, 2024	Executive	Esther Rajavelu	November 8, 2024	Sell	17,200	1.30	22,400

[Company Information]

Spero Therapeutics, Inc., formerly known as Spero Therapeutics, LLC, was incorporated in December 2013 under Delaware law. The company is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapies for MDR bacterial infections. The company also owns a platform technology called “Potential Platform,” which the company believes will develop drugs capable of expanding the spectrum and efficacy of existing antibiotics, including previously inactive antibiotics, to combat Gram-negative bacteria. The company believes that if successfully developed and approved, these new products could have a meaningful impact on patients treating MDR infections in community and hospital settings and hold significant commercial potential.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes